Xultophy Label Update at Parity with Soliqua
According to Drugs@FDA, Xultophy label was updated to expand the indication for use in patients uncontrolled on OADs. Additionally, the new label also included 3 other major changes: 1) recommended starting dose, 2) clinical data from DUAL I, DUAL IV trials and 3) a caution for audible clicks. Of note, Novo did not issue a press release on this FDA approval. Below, FENIX provides an analysis of the updated Xultophy label and its impact on the injectable market segment.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.